AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / September 18, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), ) a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on ACD440, the leading non-opioid drug candidate in the Painless platform, has been accepted for presentation at the annual pain conference to be held by the Swedish Pain Society in Uppsala, Sweden, on October 12-13.

The abstract, titled Topikal ACD440 Gel minskar smärta utlöst av temperatur-stimuli hos patienter med perifer neuropatisk smärta med sensorisk överkänslighet , will be presented at Svenskt Smärtforum 2023 by Dr. Märta Segerdahl, project leader and CMO at AlzeCure.

The presentation will include results from the completed phase II clinical trial of ACD440 in patients with peripheral neuropathic pain. This study is a double-blind, placebo-controlled, randomized crossover study aimed at evaluating the efficacy, safety and pharmacokinetics of AlzeCure’s lead candidate drug in pain, ACD440.

“The study results showed a significant positive effect of ACD440 on temperature-triggered pain, which confirms our previous phase Ib study with the substance. These promising data together with the very good tolerability observed in patients further strengthen our hypotheses and bode well for the continued clinical development of ACD440,” said Dr. Segerdahl.

AlzeCure’s drug candidate ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. The discovery of TRPV1 that underlies the project was awarded the Nobel Prize in Physiology or Medicine in 2021. There is thus a strong scientific basis for this biological mechanism, including its relationship to pain signaling. ACD440 completed a positive phase Ib study in 2021. It showed both very good tolerability and safety, but also a potent, long-lasting pain-relieving effect of the substance that is applied as a gel to the skin.

“ACD440 has in this clinical phase II study now shown proof-of-mechanism also in patients with significant analgesic effects on temperature-triggered pain. This in an indication area where up to 80% of the patients do not get a satisfactory effect with their current treatments. Neuropathic pain is the single largest market segment in pain management, with annual sales of over USD 11 billion, reflecting the large number of people affected,” said Martin Jönsson, CEO of AlzeCure Pharma.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 , is the company’s Certified Adviser. For more information, please visit .

About Neuropathic pain
Neuropathic pain affects approximately 7-8 percent of the total global adult population, approximately 600 million individuals. Some patients, with indications such as diabetes and HIV, are affected to a greater extent, where approximately 25 and 35 percent respectively of the patients experience neuropathic pain.

Peripheral neuropathic pain is the result of various types of damage to the nerve fibers, such as toxic, traumatic or nerve compression injuries as well a metabolic and infectious diseases. Common symptoms are painful tingling that can be described as “pins and needles”, or choking or burning pain, as well as the feeling of getting an electric shock. Patients may also experience allodynia (pain caused by a stimulus that usually does not cause pain) or hyperalgesia (increased pain from a stimulus that normally provokes pain).

The market for neuropathic pain is characterized by a major medical need in all indications and in all major markets, where about 70-80 percent of patients do not get effective pain relief with existing treatment. Due to the risk of abuse, overdose and secondary damage, people now try to avoid opiates as first-line treatment for pain conditions. Despite this treatment problem, these preparations are still used frequently, and therefore the need for new treatments that are not opiates is very great.

The patient population will grow, among other things, due to an aging population and increased number of long-term cancer survivors and increasing prevlance of type-2 diabetes.

The global market for neuropathic pain was valued at $11 billion in 2020 and is expected to grow to $25 billion by 2027.

Image Attachments

CEO Martin Jönsson CMO Märta Segerdahl 2023


AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference

SOURCE: AlzeCure Pharma

View source version on

error: Content is protected !!